Tokyo/Works/Assay0
From 2007.igem.org
(→Procedure:) |
|||
| Line 26: | Line 26: | ||
===Procedure:=== | ===Procedure:=== | ||
<br>[[Tokyo/AHL assay Standard protocol |AHL assay Standard protocol ]] | <br>[[Tokyo/AHL assay Standard protocol |AHL assay Standard protocol ]] | ||
| + | |||
| + | ===Results and Conclusion=== | ||
| + | |||
[[Image:hybridgraph2.JPG|thumb|350px| '''Fig.1: '''Result]] | [[Image:hybridgraph2.JPG|thumb|350px| '''Fig.1: '''Result]] | ||
[[Image:hybridgraph.JPG|thumb|300px| '''Fig.2: '''Result summary]] | [[Image:hybridgraph.JPG|thumb|300px| '''Fig.2: '''Result summary]] | ||
Revision as of 13:05, 24 October 2007
Works top 0. Hybrid promoter 1. Formulation 2. Assay1 3. Simulation 4. Assay2 5. Future works
Purpose 1:
To check if LacI hybrid promoter is activated by AHL and repressed by LacI.
Purpose 2:
To obtain parameters of LacI hybrid promoter for computational simulation.
Samples:
1. pTrc99A + [LacI hybrid promoter – GFP] (LacI+)
2. pBR322 TetR + [LacI hybrid promoter – GFP] (lacI-)
3. pTrc99A + [placQI – GFP] (placQI is constitutive promoter)
4. pTrc99A + [LacI promoter – GFP]
5. pBR322 TetR + [LacI promoter – GFP]
Repressor LacI expression:
pTrc99A expresses LacI
pBR322 TetR does NOT express LacI
Antibiotics resistance:
pTrc99A gives ampicillin-resistance
pBR322 TetR gives ampicillin-resistance
[LacI hybrid promoter – GFP] gives kanamicin-resistance
[placQI – GFP] gives kanamicin-resistance
Procedure:
Results and Conclusion
